Bossé R, Gerold M, Fischli W, Holck M, Escher E
Département de Pharmacologie, Faculté de Médecine, Université de Sherbrooke, Québec, Canada.
J Cardiovasc Pharmacol. 1990;16 Suppl 4:S50-5. doi: 10.1097/00005344-199016004-00011.
[Sar1,Phe(Br5)8] angiotensin II (Br5Ang II) is a specific, quasi-irreversible antagonist of angiotensin II (Ang II) in vitro. In vivo, this compound is a very potent, Ang II-specific antagonist with a very long duration of action against Ang II-induced blood pressure (BP) increases. In the "low-sodium" dog, this compound induces a prolonged BP reduction during and after intravenous infusion at doses comparable to cilazapril, a potent ACE inhibitor. The physicochemical and pharmacokinetic behavior of this peptide was therefore assessed to understand and interpret the prolonged antagonistic and antihypertensive activity of this peptide. Binding studies using beef adrenocortical membranes indicated specific binding of Br5Ang and related analogues to Ang II receptors with a Kd of 1.41 x 10(-9) M against iodinated [Sar1, D-Phe8]Ang II, a standard radioligand antagonist. Iodinated Br5AngII exhibited a very high degree of nonspecific binding to the membranes. It had an octanol-water partitioning coefficient of log P of + 0.903, a coefficient 84-fold higher than for [125I][Sar1, D-Phe8]Ang II. Association kinetics of [125I]Br5Ang II were similar to the standard ligand [125I] [Sar1, D-Phe8]Ang II, but the half-life of dissociation was four times higher (60 vs. 15 min at 20 degrees C). Molecular modeling indicates a practically identical conformational behavior of both peptides, Br5Ang II and [Sar1, D-Phe8]Ang II but with an expanded hydration shell over the Br5 residue. It is concluded that the prolonged duration of action is due to the increased hydrophobicity of the peptide, which leads to a slow dissociation from the Ang II receptor.(ABSTRACT TRUNCATED AT 250 WORDS)
[Sar1,Phe(Br5)8]血管紧张素II(Br5血管紧张素II)在体外是血管紧张素II(血管紧张素II)的一种特异性、准不可逆拮抗剂。在体内,该化合物是一种非常强效的、血管紧张素II特异性拮抗剂,对血管紧张素II诱导的血压(BP)升高具有很长的作用持续时间。在“低钠”犬中,该化合物在静脉输注期间及之后,以与强效血管紧张素转换酶抑制剂西拉普利相当的剂量诱导血压长时间降低。因此,对该肽的物理化学和药代动力学行为进行了评估,以理解和解释该肽延长的拮抗和降压活性。使用牛肉肾上腺皮质膜的结合研究表明,Br5血管紧张素II及相关类似物与血管紧张素II受体有特异性结合,相对于碘化[Sar1,D-Phe8]血管紧张素II(一种标准放射性配体拮抗剂),其解离常数(Kd)为1.41×10^(-9) M。碘化Br5血管紧张素II与膜表现出非常高程度的非特异性结合。它的辛醇-水分配系数log P为+0.903,比[125I][Sar1,D-Phe8]血管紧张素II高84倍。[125I]Br5血管紧张素II的结合动力学与标准配体[125I][Sar1,D-Phe8]血管紧张素II相似,但解离半衰期高四倍(20℃时分别为60分钟和15分钟)。分子建模表明,Br5血管紧张素II和[Sar1,D-Phe8]血管紧张素II这两种肽的构象行为几乎相同,但Br5残基上有扩展的水合壳。得出的结论是,作用持续时间延长是由于该肽疏水性增加,导致其从血管紧张素II受体缓慢解离。(摘要截短为250字)